Nxera – Talk Bio

Nxera Pharma and Antiverse Collaborate to Develop Novel GPCR-Targeted Antibody Therapeutics Using Generative AI

6 months ago talkbio0Tagged Antibodies, Antiverse, Biopharma collaboration, Generative AI, GPCR-targeted antibodies, Nxera, Pharma

Nxera Pharma, Antiverse, GPCR-targeted antibodies, Generative AI, Antibody therapeutics, Biopharma collaboration

Japanese Regulators Approve Medications from Amgen, Eli Lilly, Takeda, and Nxera

7 months ago talkbio0Tagged amgen, Drug Industry, Eli, Eli Lilly, Japanese language, Nxera, Regulators (device), regulatory, Takeda

Japanese regulators, medication approvals, Amgen, Eli Lilly, Takeda, Nxera, pharmaceutical industry, regulatory updates

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis